Prehabilitation in Ovarian Cancer Patients During Chemiotherapy Before Cytoreductive Surgery.
NCT ID: NCT07058753
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
100 participants
INTERVENTIONAL
2025-07-01
2031-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Many studies have shown a positive effect of prehabilitation on postoperative results, mainly reducing the number of postoperative complications and shortening the hospitalization time.
The assumed time of prehabilitation is 2-6 weeks, but in the case of oncology patients, the procedure should not be delayed only for the sake of prehabilitation.
Our study includes oncology patients with ovarian cancer who are referred for neoadjuvant chemotherapy before interval cytoreductive surgery. The assumption of the study is an intensive course of prehabilitation during neoadjuvant treatment, which should provide significantly better postoperative results.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Connected Prehabilitation Program During Neo Adjuvant Chemotherapy
NCT04451369
Prehabilitation in Gynaecological Cancer Patients
NCT04789694
Prehabilitation for Ovarian Cancer Patients
NCT05364879
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors
NCT03641287
Exercise Preconditioning in Ovarian Cancer
NCT05029154
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intense course of prehabilitation
Patients undergoing intense prehabilitation program
Prehabilitation. An intensive prehabilitation for NACT patients
Patients referred to NACT (neoadjuvant chemotheraphy) for advanced ovarian cancer will undergo an intensive course of prehabilitation including physical exercise, a high-protein diet, protein and vitamin supplementation, optimization of laboratory test results, and psychological support will be provided.
Standard preoperative care
Patients with standard preoperative care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prehabilitation. An intensive prehabilitation for NACT patients
Patients referred to NACT (neoadjuvant chemotheraphy) for advanced ovarian cancer will undergo an intensive course of prehabilitation including physical exercise, a high-protein diet, protein and vitamin supplementation, optimization of laboratory test results, and psychological support will be provided.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No possibility of performing primary debulking surgery (Fagotti score \> 8 points). Referral patient for neoadjuvant chemotherapy
* Consent to participate in the study
* Age over 18 years
Exclusion Criteria
* Lack of consent to participate in the study
* Aletti score \< 4 points in interval debulking surgery
* Severe neurological/psychiatric disorders that make contact with the patient difficult
18 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Silesia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marcin Zębalski
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Krzysztof Nowosielski, MD, PhD
Role: STUDY_CHAIR
Department of Gynecology, Obstetrics and Gynecological Oncology, University Clinical Center of the Medical University of Silesia
Marcin A Zębalski, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Gynecology, Obstetrics and Gynecological Oncology, University Clinical Center of the Medical University of Silesia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gynecology, Obstetrics and Gynecological Oncology, University Clinical Center of the Medical University of Silesia
Katowice, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PREH/2025-2-1
Identifier Type: REGISTRY
Identifier Source: secondary_id
PREH/2025-2-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.